Barclays PLC Regeneron Pharmaceuticals, Inc. Transaction History

Barclays PLC

$288 Billion
Q1 2024

A detailed history of Barclays PLC transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Barclays PLC holds 343,618 shares of REGN stock, worth $337 Million. This represents 0.11% of its overall portfolio holdings.

Number of Shares

343,618

Previous 298,237 15.22%

Holding current value

$337 Million

Previous $262 Million 26.26%

% of portfolio

0.11%

Previous 0.1%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$902.69 - $993.35 $41 Million - $45.1 Million	45,381 Added 15.22%	343,618 $331 Million
Q4 2023 Feb 15, 2024	BUY	$775.18 - $881.7 $33.6 Million - $38.2 Million	43,367 Added 17.02%	298,237 $262 Million
Q3 2023 Nov 07, 2023	SELL	$692.45 - $844.37 $16.7 Million - $20.4 Million	-24,114 Reduced 8.64%	254,870 $210 Million
Q2 2023 Aug 03, 2023	BUY	$700.03 - $830.35 $71.9 Million - $85.3 Million	102,689 Added 58.25%	278,984 $200 Million
Q1 2023 May 04, 2023	SELL	$680.49 - $826.97 $35.3 Million - $42.9 Million	-51,879 Reduced 22.74%	176,295 $145 Million

Q4 2022 Feb 13, 2023	BUY	$705.89 - $766.39 $51.1 Million - $55.4 Million	72,348 Added 46.43%	228,174 $165 Million
Q3 2022 Nov 03, 2022	BUY	$573.97 - $724.32 $20.4 Million - $25.8 Million	35,584 Added 29.59%	155,826 $107 Million
Q2 2022 Aug 12, 2022	SELL	$548.35 - $738.84 $22.2 Million - $30 Million	-40,548 Reduced 25.22%	120,242 $71.1 Million
Q1 2022 May 16, 2022	SELL	$595.12 - $698.43 $196 Million - $230 Million	-328,819 Reduced 67.16%	160,790 $112 Million
Q4 2021 Feb 14, 2022	BUY	$543.48 - $670.97 $93.7 Million - $116 Million	172,347 Added 54.32%	489,609 $309 Million
Q3 2021 Nov 09, 2021	BUY	$574.03 - $680.96 $80.1 Million - $95 Million	139,464 Added 78.44%	317,262 $192 Million
Q2 2021 Aug 13, 2021	BUY	$472.8 - $558.54 $9.25 Million - $10.9 Million	19,565 Added 12.36%	177,798 $99.3 Million
Q1 2021 May 13, 2021	SELL	$446.73 - $548.2 $6.68 Million - $8.2 Million	-14,949 Reduced 8.63%	158,233 $74.9 Million
Q4 2020 Feb 11, 2021	BUY	$478.3 - $607.98 $14.1 Million - $17.9 Million	29,514 Added 20.54%	173,182 $83.7 Million
Q3 2020 Nov 12, 2020	SELL	$544.75 - $658.21 $12.6 Million - $15.3 Million	-23,180 Reduced 13.89%	143,668 $80.4 Million
Q2 2020 Aug 12, 2020	BUY	$493.32 - $643.92 $788,325 - $1.03 Million	1,598 Added 0.97%	166,848 $104 Million
Q1 2020 May 13, 2020	SELL	$336.18 - $494.43 $25.9 Million - $38.1 Million	-77,090 Reduced 31.81%	165,250 $80.7 Million
Q4 2019 Feb 10, 2020	SELL	$274.13 - $376.51 $6.54 Million - $8.98 Million	-23,854 Reduced 8.96%	242,340 $91 Million
Q3 2019 Nov 14, 2019	BUY	$273.46 - $318.39 $20.4 Million - $23.8 Million	74,612 Added 38.95%	266,194 $73.8 Million
Q2 2019 Aug 14, 2019	BUY	$299.6 - $414.82 $20.8 Million - $28.7 Million	69,291 Added 56.66%	191,582 $60 Million
Q1 2019 May 15, 2019	BUY	$372.08 - $439.57 $983,035 - $1.16 Million	2,642 Added 2.21%	122,291 $50.2 Million
Q4 2018 Feb 14, 2019	SELL	$335.82 - $403.04 $13.4 Million - $16.1 Million	-39,872 Reduced 24.99%	119,649 $44.7 Million
Q3 2018 Nov 14, 2018	BUY	$351.14 - $408.51 $9.29 Million - $10.8 Million	26,444 Added 19.87%	159,521 $64.5 Million
Q2 2018 Aug 14, 2018	SELL	$284.6 - $344.99 $19.8 Million - $24 Million	-69,608 Reduced 34.34%	133,077 $45.9 Million
Q1 2018 May 15, 2018	BUY	$315.82 - $393.78 $13.5 Million - $16.8 Million	42,672 Added 26.67%	202,685 $69.8 Million
Q4 2017 Feb 14, 2018	SELL	$358.63 - $469.95 $11.4 Million - $15 Million	-31,834 Reduced 16.59%	160,013 $60.2 Million
Q3 2017 Nov 14, 2017	BUY	$431.38 - $504.0 $82.8 Million - $96.7 Million	191,847	191,847 $85.8 Million

Others Institutions Holding REGN

# of Institutions

1,426

Shares Held

82.1M

Call Options Held

835K

Put Options Held

1.46M

View Full List

About REGENERON PHARMACEUTICALS, INC.

Ticker REGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,190,000
Market Cap $105B
Description
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...

More about REGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account